Elezanumab

Elezanumab (ABT-555) is a potent human anti-RGMa monoclonal antibody.Elezanumab exerts its inhibitory effect on RGMa-mediated BMP signaling through the SMAD1/5/8 pathway, with an IC50 of approximately 97 pM.Elezanumab promotes neuroregeneration, neuroprotection, and neural restoration in models of neuronal injury and demyelination. Elezanumab promotes the growth of corticospinal axons into spinal gray matter and enhances serotonergic innervation in the ventral horn, forming synaptic connections in the caudal part of cervical lesions.